1. Home
  2. CIF vs GDTC Comparison

CIF vs GDTC Comparison

Compare CIF & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Intermediate High Income Fund

CIF

MFS Intermediate High Income Fund

HOLD

Current Price

$1.75

Market Cap

31.1M

Sector

Finance

ML Signal

HOLD

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

HOLD

Current Price

$1.62

Market Cap

24.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIF
GDTC
Founded
1988
2018
Country
United States
Singapore
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.1M
24.8M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
CIF
GDTC
Price
$1.75
$1.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
43.9K
79.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
10.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$573,193.00
Revenue This Year
N/A
$5.37
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
63.03
52 Week Low
$1.47
$1.50
52 Week High
$1.77
$4.05

Technical Indicators

Market Signals
Indicator
CIF
GDTC
Relative Strength Index (RSI) 53.15 38.67
Support Level $1.68 $1.71
Resistance Level $1.75 $1.68
Average True Range (ATR) 0.02 0.12
MACD 0.00 -0.01
Stochastic Oscillator 66.48 19.55

Price Performance

Historical Comparison
CIF
GDTC

About CIF MFS Intermediate High Income Fund

Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: